P1, N=43, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Feb 2028 --> Nov 2027 | Trial primary completion date: Feb 2028 --> Nov 2027
9 months ago
Trial completion date • Trial primary completion date
P1, N=80, Recruiting, Juno Therapeutics, a Subsidiary of Celgene | Trial completion date: Jan 2025 --> Jun 2024 | Trial primary completion date: Jan 2025 --> Jun 2024
2 years ago
Trial completion date • Trial primary completion date